Prothrombin Times Outside the Therapeutic Range in Otherwise Stable Patients
NCT00814177 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160
Last updated 2012-08-01
Summary
Warfarin is very effective for the prevention of blood clots (thrombosis). A test of coagulation, the prothrombin time (PT) is used to monitor the effect. The PT response to warfarin can fluctuate as a result of interactions with a large number of other drugs, food or herbal agents as well as for no apparent reason. Thus, frequent monitoring of the PT and dose adjustments according to the results are required. One third of our patients remain on the same maintenance dose over 6 months. However, also these patients sometimes have a PT result moderately outside the therapeutic range without any obvious explanation. Too short PTs may be due to missed dose(s) or more dark green vegetables in the diet. Too long PTs may be due to a course of antibiotic therapy or less dark green vegetables. Laboratory errors may also occur and can cause deviations in any direction. Most likely, unnoticed fluctuations in the PT occur as well between the time points of monitoring.
There are no guidelines on how to manage the treatment in this situation but there are some typical "behaviours".
Behavior A: Some physicians simply let the patient continue with the same dose. "It is extremely unlikely that the very temporary dose adjustment has any effect on the PT result 4 weeks later and this is a "cosmetic procedure"." Behavior B: Others recommend the patients to take ½ - 1 additional dose in case of short PT and to skip a dose or take half dose in case of long PT, and thereafter to continue with the usual dose. "The investigators need to quickly correct the temporary aberration in order to avoid thrombotic or bleeding complications the next few days.
This may seem like an issue of no importance. The investigators are however performing a series of studies to evaluate if these stable patients can be managed with blood tests less often than every 4 weeks. For that purpose it is important to know how often and why aberrant results occur, the implication and to what extent they can be ignored.
The investigators hypothesis is that in patients with very stable PT-results and unchanged dose for 3 months, should continue with exactly the same maintenance dose, even when the result unexpectedly is slightly above or below the therapeutic range. The investigators believe that most of these occasional PT-results outside the therapeutic range are due to laboratory errors, perhaps missed doses by the patient or temporary change in diet or medications.
Conditions
- Atrial Fibrillation
- Venous Thromboembolism
- Ischemic Stroke
- Myocardial Infarction
Interventions
- DRUG
-
warfarin
No change: Continue without any change in spite of prothrombin time outside the therapeutic range.
- DRUG
-
warfarin
Change: Increase one dose in case prothrombin time is below the therapeutic range; delete or reduce one dose in case prothrombin time is above the therapeutic range.
Sponsors & Collaborators
-
Hamilton Health Sciences Corporation
lead OTHER
Principal Investigators
-
Sam Schulman, MD, PhD · McMaster University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-07-31
- Primary Completion
- 2009-01-31
- Completion
- 2009-04-30
Countries
- Canada
Study Locations
More Related Trials
-
Study to Determine the Accuracy of Prothrombin Time of Warfarinised Blood
NCT01375725 ·Status: COMPLETED
-
Does Low Dose Oral Vitamin K Improve International Normalized Ratio (INR) Stability?
NCT00990158 ·Status: COMPLETED ·Phase: PHASE3
-
Absence of Residual Vein Thrombosis Permits to Withdrawn Oral Anticoagulants
NCT00623987 ·Status: COMPLETED ·Phase: PHASE4
-
Reinitiation of Anticoagulation After Temporary Withdrawal of Vitamin K Antagonist
NCT01348074 ·Status: COMPLETED ·Phase: PHASE2
-
PRospective Evaluation Comparing Initiation of Warfarin StrategiEs (PRECISE): Pharmacogenetic-guided Versus Usual Care
NCT00377143 ·Status: WITHDRAWN ·Phase: PHASE4
-
Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis
NCT00005684 ·Status: COMPLETED
-
To Establish a Novel Prototype of Clinical Pharmacy Services by Warfarin Consultation in a Pharmacist Clinic
NCT01972971 ·Status: UNKNOWN ·Phase: NA
-
3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE
NCT00365950 ·Status: COMPLETED ·Phase: PHASE4
-
Early Versus Late Resumption of Anticoagulation in Patients With Both High Thrombosis Risk and Major HEmoRrhage
NCT02091479 ·Status: TERMINATED ·Phase: PHASE3
-
Tapered Warfarin or Interrupted Warfarin With Heparin Bridging for Pacemaker or Defibrillator Implantation
NCT02094157 ·Status: TERMINATED ·Phase: PHASE3
-
COMPARISON OF WARFARIN AND RIVAROXABAN IN THE TREATMENT OF LOWER LIMB DEEP VENOUS THROMBOSIS
NCT07077954 ·Status: COMPLETED ·Phase: PHASE1
-
Blood Donation From Warfarin Users for the Development of POC INR Monitor
NCT02355730 ·Status: UNKNOWN ·Phase: NA
-
Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin)
NCT00933738 ·Status: COMPLETED
-
Prevention of Thrombosis Recurrence in Patients With Low Circulating Levels of Antithrombin.
NCT01382550 ·Status: UNKNOWN
-
Fiix-prothrombin Time for Monitoring Warfarin
NCT01565239 ·Status: COMPLETED ·Phase: PHASE2
-
Residual Vein Thrombosis Establishes the Optimal Duration of Oral Anticoagulants
NCT00438230 ·Status: COMPLETED ·Phase: PHASE4
-
Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal
NCT03064035 ·Status: COMPLETED ·Phase: PHASE4
-
Effectiveness and Safety of Different Antithrombotic Therapy for the Treatment of Ventricular Thrombus
NCT05006677 ·Status: UNKNOWN
-
Efficacy and Safety of Prothromplex Total (Prothrombin Complex Concentrate) in Oral Anticoagulant Reversal
NCT01159210 ·Status: COMPLETED ·Phase: PHASE4
-
Use of Phytonadione to Reduce International Normalized Ratio (INR) Variability in Patients on Long-term Warfarin Therapy
NCT01474460 ·Status: COMPLETED ·Phase: NA
-
Evaluation of a Pharmacogenetic-based Warfarin Dosing Algorithm in Patients
NCT02592980 ·Status: UNKNOWN ·Phase: PHASE4
-
Assessing the Ability of Warfarin Treated Patients to Predict Their INR
NCT02764112 ·Status: COMPLETED
-
The Association of Warfarin Dosage and Plasma Enantiomer Concentration With the Gene Polymorphisms of CYP and VKOR
NCT00247702 ·Status: UNKNOWN ·Phase: NA
-
The Home INR Study
NCT00032591 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of Warfarin Dosing Using Decision Model Versus Pharmacogenetic Algorithm
NCT00511173 ·Status: COMPLETED ·Phase: PHASE4